Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

ABSTRACT:

Background

Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection are needed.

Objective

To evaluate the prognostic value of immune and stromal signatures in MIBC treated with TMT.

Design, setting, and participants

We used a clinical-grade platform to perform transcriptome-wide gene expression profiling of primary tumors from 136 MIBC patients treated with TMT at a single institution. We observed 60 overall survival events at 5yr, and median follow-up time for patients without an event was 5.0yr (interquartile range 3.1, 5.0). Expression data from another cohort of 223 MIBC patients treated with neoadjuvant chemotherapy (NAC) and RC were also analyzed.<

SUBMITTER: Efstathiou JA 

PROVIDER: S-EPMC6571058 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature